Latest news with #RESET®
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
Morphic Medical Announces CEO Transition
BOSTON, Aug. 5, 2025 /PRNewswire/ — Morphic Medical, an innovative MedTech company that has pioneered minimally invasive treatment of obesity and cardiometabolic disorders, today announced a leadership transition as part of its continued evolution and growth strategy. After 5 years of dedicated service, Joe Virgilio will be transitioning out of the role of Chief Executive Officer. Under his leadership, Morphic Medical has met several significant milestones in product development, manufacturing improvements, and organizational growth, including overseeing efforts which led to the regulatory approval of RESET® under EU MDR in July of this year. The Board of Directors is pleased to announce that Mike Gutteridge will assume the role of CEO, bringing with him a wealth of experience in the bariatric endoscopy space. Mike most recently served as Vice President of Therapy Development and Commercial Operations at Morphic where he developed the companies go-to-market strategy for RESET®. 'Joe has been instrumental in shaping Morphic Medical into the company it is today,' said Mark Lerdal, Chair of the Board of Directors. 'We are grateful for his vision, leadership, and commitment to innovation and patient care. We are equally excited to welcome Mike, who shares our values and brings a successful track record of international commercialization as we enter our next phase of growth.' 'It has been a privilege to lead Morphic Medical over the past 5 years. I am proud of what our tremendous team has accomplished and am confident in the company's future under Mike. I remain committed to the mission and look forward to supporting Mike and the Board as Morphic transitions into this exciting next chapter,' Virgilio stated. Mike Gutteridge said, 'I am honored to take on the role of Chief Executive Officer at Morphic Medical, succeeding Joe Virgilio, and I am deeply grateful for his continued support as we enter this next chapter. With over 30 years in the medtech sector spanning clinical innovation, commercial strategy, market development and reimbursement, I am energized by the opportunity to lead Morphic into its next phase, a focused expansion into global markets, accelerated commercialization, and a deepening of our commitment to improving the lives of patients through effective durable therapies. As CEO, I will build on Morphic's pioneering work in GI metabolic health and continue to foster a culture of agility, purpose, and partnership both within our exceptional team and with our growing network of clinicians, researchers, and investors. Together, we will ensure Morphic's technology reaches the people who need it most, while creating sustainable value through responsible growth. This is an exciting time for our company, and I am proud to help shape what comes next.' The leadership transition will be carefully managed over the coming months to ensure continuity across all operations, stakeholders, and partnerships. About MorphicMorphic Medical is the developer of RESET, an endoscopically delivered therapy which offers a non-surgical, alternative treatment for morbid obesity and/or obesity in the presence of concurrent cardiometabolic risk factor, e.g., type 2 diabetes and/or dyslipidemia. RESET is not approved for sale in the United States and is limited by federal law to investigational use only. Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts. For more information, please visit or follow us on Twitter and LinkedIn. Morphic Medical Media Contact:Investor Relationsinvestor@ (781) 357-3296
Business Wire
21-04-2025
- Health
- Business Wire
PursueCare to Spotlight Next-Gen Digital Therapeutics at the 56 th American Society of Addiction Medicine (ASAM) Conference in Denver April 24-27
DENVER--(BUSINESS WIRE)--PursueCare, a leading provider of virtual addiction treatment and specialized pharmacy services, is proud to announce its participation in the 56th Annual American Society of Addiction Medicine (ASAM) Conference in Denver, Colo., April 24-27, 2025. The event gathers top experts, clinicians, and innovators in addiction medicine to advance science, practice, and policy in the field. With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions. Share Honoring a Visionary in Addiction Medicine—Dr. Jason Kirby Named 2025 ASAM Distinguished Fellow PursueCare's Medical Director, Dr. Jason Kirby, DO, MBA, DFASAM, has been named a 2025 Distinguished Fellow of ASAM, one of the society's highest honors. This prestigious designation recognizes Dr. Kirby's enduring commitment to evidence-based, outcomes-driven care and his leadership in improving access to treatment for individuals with substance use disorder (SUD). 'I began this journey nearly a decade ago with a mission to provide compassionate, science-backed care for people living with addiction. Being recognized as a Distinguished Fellow by ASAM is a profound honor,' said Dr. Kirby. 'It's a privilege to stand alongside so many esteemed leaders who are transforming the future of addiction medicine.' With dual board certifications in addiction medicine and family medicine, and deep expertise in healthcare policy and population health, Dr. Kirby exemplifies the innovative and empathetic leadership PursueCare brings to the field. Visit PursueCare at Booth #325—Experience RESET® and RESET-O® Conference attendees are invited to Booth #325 to experience PursueCare's cutting-edge, virtual-first addiction treatment platform. The company will spotlight its latest advancements, including: RESET® and RESET-O®—the first and only FDA-authorized digital therapeutics for SUD and opioid use disorder (OUD). Watch the video Transforming Addiction Treatment with RESET®. Tools that offer 24/7 recovery support, blending cognitive behavioral therapy (CBT), contingency management, and real-time progress tracking within PursueCare's secure, proprietary smartphone applications. These groundbreaking therapeutics are seamlessly embedded into PursueCare's care model, extending the reach and impact of virtual addiction care. Elevating the Standards of Recovery 'Dr. Kirby's recognition as a Distinguished Fellow is a proud moment for everyone at PursueCare,' said Nick Mercadante, Founder and Chief Executive Officer. 'His tireless work to expand access and improve outcomes in virtual addiction treatment reflects our mission to reimagine what recovery looks like for people everywhere.' With innovation at its core, PursueCare continues to lead the charge in transforming addiction care through accessible, scalable, and data-driven solutions. About PursueCare PursueCare provides personalized virtual addiction treatment for individuals across states (CT, KY, MA, ME, NH, OH, and WV). Our mission is to increase access to chronic care through telehealth. Patients engage with a multi-disciplinary team providing medical care, counseling, psychiatry, and pharmacy. FDA-authorized digital cognitive behavioral therapy, RESET® and RESET-O®, supports recovery 24/7. We accept private insurance, Medicare, and Medicaid. Learn more at and
